ClinicalTrials.Veeva

Menu

Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women

Novartis logo

Novartis

Status and phase

Completed
Phase 1

Conditions

Postmenopausal Osteoporosis

Treatments

Drug: Oral salmon calcitonin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00411125
CSMC021A2111

Details and patient eligibility

About

This is a phase I study to analyze bioavailability and pharmacodynamic of two different variants of oral salmon calcitonin (SMC021) in postmenopausal women

Sex

Female

Ages

40 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Healthy postmenopausal women

Exclusion criteria

  • Previous treatment with other osteoporosis medication

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems